Technical Data

D1499
Clone Type
Polyclonal
Host
Rabbit
Source
Human
Isotype
IgG
Grade
Highly Purified
Applications
WB
Crossreactivity
Hu
Shipping Temp
Blue Ice
Storage Temp
-20°C
Rabbit Anti-DcR1 (TRAIL-R3, TRID, LIT, TRAIL Decoy Receptor1)

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT (2-7) and DcR2/TRAIL-R4/ TRUNDD (8-10). DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues. But not in most cancer cell lines (2,3) Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis (2,3).

Applications
Suitable for use in ELISA, Western Blotting. Other applications not tested.
Recommended Dilution
Western Blotting: 1:500-1:1000. An ~65kD band can be detected (6). Optimal dilutions to be determined by the researcher.
Positive Control: Whole cell lysate from HeLa cells
Storage and Stability
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Immunogen
Peptide corresponding to amino acids 149 to 167 at extracellular domain (ED) of human DcR1 precursor (2-3).
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Purity
Supplied as chromatographically purified IgG
Specificity
Recognizes human DcR1 (ED) TRAIL-R3, TRID, LIT

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
1. Pan G; O’Rourke K; Chinnaiyan et al.. The receptor for the cytotoxic ligand TRAIL. Science; 1997;276:111-113 2. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8 3. Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21 4. Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186(7):1165-70 5. MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272(41):25417-20 6. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997;416(3):329-34 7. Mongkolsapaya J, Cowper AE, Xu XN, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998;160(1):3-6 8. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6 9. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20 10. Pan G, Ni J, Yu G, et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998;424:41-5 (RD0300)
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net